Latest Insider Transactions at Catalyst Pharmaceuticals, Inc. (CPRX)
This section provides a real-time view of insider transactions for Catalyst Pharmaceuticals, Inc. (CPRX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of CATALYST PHARMACEUTICALS, INC. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of CATALYST PHARMACEUTICALS, INC.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 13
2024
|
Steve Miller Chief Op. & Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
235,000
+20.31%
|
$940,000
$4.01 P/Share
|
|
Dec 10
2024
|
Charles B O'Keeffe Director |
BUY
Exercise of conversion of derivative security
|
Direct |
40,000
+5.21%
|
$160,000
$4.01 P/Share
|
|
Dec 10
2024
|
Steve Miller Chief Op. & Scientific Officer |
SELL
Open market or private sale
|
Direct |
50,000
-6.78%
|
$1,050,000
$21.93 P/Share
|
|
Dec 10
2024
|
Steve Miller Chief Op. & Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+6.35%
|
$200,000
$4.01 P/Share
|
|
Dec 09
2024
|
Jeffrey Del Carmen Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,355
-11.54%
|
-
|
|
Dec 09
2024
|
Jeffrey Del Carmen Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,039
+28.26%
|
-
|
|
Dec 09
2024
|
Preethi Sundaram Chief Strategy Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,415
-7.45%
|
-
|
|
Dec 09
2024
|
Preethi Sundaram Chief Strategy Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,855
+17.46%
|
-
|
|
Dec 09
2024
|
Donald A Denkhaus Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,413
+0.32%
|
-
|
|
Dec 09
2024
|
Charles B O'Keeffe Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,413
+0.21%
|
-
|
|
Dec 09
2024
|
Patrick J Mcenany Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,533
+0.08%
|
-
|
|
Dec 09
2024
|
Molly Harper Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,413
+50.0%
|
-
|
|
Dec 09
2024
|
Brian Elsbernd Chief Compliance/Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,720
-0.97%
|
-
|
|
Dec 09
2024
|
Brian Elsbernd Chief Compliance/Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,067
+3.81%
|
-
|
|
Dec 09
2024
|
David S Tierney Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,413
+0.4%
|
-
|
|
Dec 09
2024
|
Gary Ingenito Chief Med. & Reg. Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,891
-4.92%
|
-
|
|
Dec 09
2024
|
Gary Ingenito Chief Med. & Reg. Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,349
+11.12%
|
-
|
|
Dec 09
2024
|
Tamar Thompson Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,413
+50.0%
|
-
|
|
Dec 09
2024
|
Steve Miller Chief Op. & Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
11,872
+1.7%
|
-
|
|
Nov 27
2024
|
Molly Harper Director |
SELL
Open market or private sale
|
Direct |
17,500
-100.0%
|
$385,000
$22.0 P/Share
|
|
Nov 27
2024
|
Molly Harper Director |
BUY
Exercise of conversion of derivative security
|
Direct |
17,500
+50.0%
|
$87,500
$5.78 P/Share
|
|
Nov 27
2024
|
Gary Ingenito Chief Med. & Reg. Officer |
SELL
Open market or private sale
|
Direct |
12,000
-9.88%
|
$264,000
$22.71 P/Share
|
|
Nov 27
2024
|
Gary Ingenito Chief Med. & Reg. Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
12,000
+15.92%
|
$48,000
$4.01 P/Share
|
|
Nov 26
2024
|
Brian Elsbernd Chief Compliance/Legal Officer |
SELL
Open market or private sale
|
Direct |
13,256
-3.79%
|
$278,376
$21.62 P/Share
|
|
Nov 26
2024
|
Brian Elsbernd Chief Compliance/Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
60,000
+13.81%
|
$240,000
$4.01 P/Share
|
|
Nov 20
2024
|
Gary Ingenito Chief Med. & Reg. Officer |
SELL
Open market or private sale
|
Direct |
38,000
-42.51%
|
$798,000
$21.2 P/Share
|
|
Nov 20
2024
|
Gary Ingenito Chief Med. & Reg. Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
38,000
+29.83%
|
$152,000
$4.01 P/Share
|
|
Nov 20
2024
|
Patrick J Mcenany Director |
SELL
Open market or private sale
|
Direct |
72,500
-1.59%
|
$1,522,500
$21.29 P/Share
|
|
Nov 20
2024
|
Patrick J Mcenany Director |
BUY
Exercise of conversion of derivative security
|
Direct |
72,500
+1.57%
|
$217,500
$3.54 P/Share
|
|
Nov 19
2024
|
Patrick J Mcenany Director |
SELL
Open market or private sale
|
Direct |
98,345
-2.15%
|
$2,065,245
$21.19 P/Share
|
|
Nov 19
2024
|
Patrick J Mcenany Director |
BUY
Exercise of conversion of derivative security
|
Direct |
98,345
+2.1%
|
$295,035
$3.54 P/Share
|
|
Nov 14
2024
|
Patrick J Mcenany Director |
SELL
Open market or private sale
|
Direct |
44,655
-0.99%
|
$937,755
$21.75 P/Share
|
|
Nov 14
2024
|
Patrick J Mcenany Director |
BUY
Exercise of conversion of derivative security
|
Direct |
44,655
+0.98%
|
$133,965
$3.54 P/Share
|
|
Nov 13
2024
|
Patrick J Mcenany Director |
SELL
Open market or private sale
|
Direct |
92,500
-2.02%
|
$2,035,000
$22.98 P/Share
|
|
Nov 13
2024
|
Patrick J Mcenany Director |
BUY
Exercise of conversion of derivative security
|
Direct |
92,500
+1.98%
|
$277,500
$3.54 P/Share
|
|
Nov 12
2024
|
Patrick J Mcenany Director |
SELL
Open market or private sale
|
Direct |
262,000
-2.83%
|
$6,026,000
$23.31 P/Share
|
|
Nov 12
2024
|
Patrick J Mcenany Director |
BUY
Exercise of conversion of derivative security
|
Direct |
262,000
+2.73%
|
$786,000
$3.78 P/Share
|
|
Nov 11
2024
|
Patrick J Mcenany Director |
SELL
Open market or private sale
|
Direct |
230,000
-4.89%
|
$5,290,000
$23.55 P/Share
|
|
Nov 11
2024
|
Patrick J Mcenany Director |
BUY
Exercise of conversion of derivative security
|
Direct |
230,000
+4.66%
|
$920,000
$4.01 P/Share
|
|
Aug 22
2024
|
Patrick J Mcenany Director |
SELL
Bona fide gift
|
Direct |
5,100
-0.11%
|
-
|
|
Aug 21
2024
|
David S Tierney Director |
SELL
Open market or private sale
|
Direct |
15,000
-4.12%
|
$300,000
$20.1 P/Share
|
|
Aug 21
2024
|
David S Tierney Director |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+3.96%
|
$60,000
$4.01 P/Share
|
|
Aug 20
2024
|
Steve Miller Chief Op. & Scientific Officer |
SELL
Open market or private sale
|
Direct |
150,000
-6.47%
|
$3,000,000
$20.35 P/Share
|
|
Aug 15
2024
|
Patrick J Mcenany Director |
SELL
Bona fide gift
|
Direct |
45,000
-0.99%
|
-
|
|
Aug 09
2024
|
Gary Ingenito Chief Med. & Reg. Officer |
SELL
Open market or private sale
|
Direct |
100,000
-66.05%
|
$1,800,000
$18.04 P/Share
|
|
Aug 09
2024
|
Gary Ingenito Chief Med. & Reg. Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
100,000
+39.78%
|
$400,000
$4.01 P/Share
|
|
Aug 09
2024
|
Jeffrey Del Carmen Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
36,058
-51.84%
|
$649,044
$18.43 P/Share
|
|
Aug 09
2024
|
Jeffrey Del Carmen Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+41.45%
|
$60,000
$2.86 P/Share
|
|
Jun 07
2024
|
Jeffrey Del Carmen Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
7,541
-29.04%
|
$120,656
$16.07 P/Share
|
|
Jun 05
2024
|
Gary Ingenito Chief Med. & Reg. Officer |
SELL
Open market or private sale
|
Direct |
80,000
-60.89%
|
$1,280,000
$16.16 P/Share
|